Metronidazol Fresenius (Metronidazole)

Metronidazole penetrates susceptible microbes and is reduced by intracellular redox proteins to form nitro radical anions. These reactive species damage microbial DNA and inhibit nucleic acid synthesis, ultimately leading to cell death of anaerobic bacteria and certain protozoa.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Healthcare professionals should follow the product label and institutional protocols.

Metronidazole is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy when the potential benefit justifies the risk. Limited data are available for breastfeeding; clinicians should weigh benefits against possible exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, providing the required quantity and your institutional credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional verification before responding with pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Metronidazol Fresenius shares the same class mechanism as tinidazole and ornidazole but differs in pharmacokinetic profile. Metronidazole has a well‑established safety record, a shorter half‑life requiring more frequent dosing, and broader clinical experience for severe anaerobic infections, whereas tinidazole offers a longer half‑life and may be preferred for oral regimens.

The product must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken. Prior to use, inspect the vial for particulate matter and ensure the solution is clear. Follow aseptic technique when preparing the intravenous infusion.

Metronidazol Fresenius is given by intravenous infusion. The vial is typically diluted with an appropriate compatible IV fluid (e.g., 5% dextrose or normal saline) and infused over 30‑60 minutes, depending on the prescribed dose and patient tolerance. Administration should be performed by qualified healthcare personnel under sterile conditions.

Serious adverse reactions include seizures, peripheral neuropathy, severe cutaneous adverse reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be monitored for neurological symptoms, skin changes, and signs of allergic reaction, especially during high‑dose or prolonged therapy.

Metronidazol Fresenius is contraindicated in individuals with a known hypersensitivity to metronidazole or any nitroimidazole component. Caution is advised in patients with severe hepatic impairment, severe renal dysfunction, or those receiving concomitant alcohol, as a disulfiram‑like reaction may occur.